As a result, the treatment of NK cells from patients with XLP with PI3K inhibitors does not further affect NK cell-cytotoxic function, whereas in healthy donors, PI3K inhibition impairs NK cell lytic function. This evidence concerns the gene PIK3CD and X-linked lymphoproliferative disease.